262 related articles for article (PubMed ID: 22017180)
21. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
Santo L; Siu KT; Raje N
Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate.
Liang YC; Lin-Shiau SY; Chen CF; Lin JK
J Cell Biochem; 1999 Oct; 75(1):1-12. PubMed ID: 10462699
[TBL] [Abstract][Full Text] [Related]
23. Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin.
Wesierska-Gadek J; Gueorguieva M; Horky M
Pol J Pharmacol; 2003; 55(5):895-902. PubMed ID: 14704484
[TBL] [Abstract][Full Text] [Related]
24. AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity.
Liu Y; Lu C; Shen Q; Munoz-Medellin D; Kim H; Brown PH
Oncogene; 2004 Oct; 23(50):8238-46. PubMed ID: 15378019
[TBL] [Abstract][Full Text] [Related]
25. P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
Grimison B; Langan TA; Sclafani RA
Cell Growth Differ; 2000 Oct; 11(10):507-15. PubMed ID: 11063124
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens.
Carroll JS; Swarbrick A; Musgrove EA; Sutherland RL
Cancer Res; 2002 Jun; 62(11):3126-31. PubMed ID: 12036924
[TBL] [Abstract][Full Text] [Related]
27. Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion.
Gray-Bablin J; Rao S; Keyomarsi K
Cancer Res; 1997 Feb; 57(4):604-9. PubMed ID: 9044834
[TBL] [Abstract][Full Text] [Related]
28. Cell cycle control in breast cancer cells.
Caldon CE; Daly RJ; Sutherland RL; Musgrove EA
J Cell Biochem; 2006 Feb; 97(2):261-74. PubMed ID: 16267837
[TBL] [Abstract][Full Text] [Related]
29. Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors.
Węsierska-Gądek J; Hackl S; Zulehner N; Maurer M; Komina O
J Cell Biochem; 2011 Jan; 112(1):273-88. PubMed ID: 21080333
[TBL] [Abstract][Full Text] [Related]
30. Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells.
Wesierska-Gadek J; Hajek SB; Sarg B; Wandl S; Walzi E; Lindner H
Biochem Pharmacol; 2008 Dec; 76(11):1503-14. PubMed ID: 18761330
[TBL] [Abstract][Full Text] [Related]
31. Cyclin-dependent kinases in breast cancer: expression pattern and therapeutic implications.
Sofi S; Mehraj U; Qayoom H; Aisha S; Asdaq SMB; Almilaibary A; Mir MA
Med Oncol; 2022 Apr; 39(6):106. PubMed ID: 35486263
[TBL] [Abstract][Full Text] [Related]
32. Cyclin-dependent kinase pathways as targets for cancer treatment.
Shapiro GI
J Clin Oncol; 2006 Apr; 24(11):1770-83. PubMed ID: 16603719
[TBL] [Abstract][Full Text] [Related]
33. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
Klein MA
Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
[TBL] [Abstract][Full Text] [Related]
34. Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia?
Wesierska-Gadek J; Krystof V
Ann N Y Acad Sci; 2009 Aug; 1171():228-41. PubMed ID: 19723060
[TBL] [Abstract][Full Text] [Related]
35. Metabolomic Applications to the Characterization of the Mode-of-Action of CDK Inhibitors.
Palomino-Schätzlein M; Pineda-Lucena A
Methods Mol Biol; 2016; 1336():211-23. PubMed ID: 26231718
[TBL] [Abstract][Full Text] [Related]
36. Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer.
Patel H; Abduljabbar R; Lai CF; Periyasamy M; Harrod A; Gemma C; Steel JH; Patel N; Busonero C; Jerjees D; Remenyi J; Smith S; Gomm JJ; Magnani L; Győrffy B; Jones LJ; Fuller-Pace F; Shousha S; Buluwela L; Rakha EA; Ellis IO; Coombes RC; Ali S
Clin Cancer Res; 2016 Dec; 22(23):5929-5938. PubMed ID: 27301701
[TBL] [Abstract][Full Text] [Related]
37. The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.
Węsierska-Gądek J; Kramer MP
Future Med Chem; 2012 Mar; 4(4):395-424. PubMed ID: 22416772
[TBL] [Abstract][Full Text] [Related]
38. The evolution of cyclin dependent kinase inhibitors in the treatment of cancer.
Jhaveri K; Burris Rd HA; Yap TA; Hamilton E; Rugo HS; Goldman JW; Dann S; Liu F; Wong GY; Krupka H; Shapiro GI
Expert Rev Anticancer Ther; 2021 Oct; 21(10):1105-1124. PubMed ID: 34176404
[No Abstract] [Full Text] [Related]
39. Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting.
Gupta A; Dagar G; Chauhan R; Sadida HQ; Almarzooqi SK; Hashem S; Uddin S; Macha MA; Akil ASA; Pandita TK; Bhat AA; Singh M
Adv Protein Chem Struct Biol; 2023; 135():21-55. PubMed ID: 37061333
[TBL] [Abstract][Full Text] [Related]
40. Cyclin-dependent kinase inhibitors: novel anticancer agents.
Mani S; Wang C; Wu K; Francis R; Pestell R
Expert Opin Investig Drugs; 2000 Aug; 9(8):1849-70. PubMed ID: 11060782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
